JPRN-UMIN000016275已完成未知
The effectiveness of peginterferon -alpha2a and the entecavir combination therapy for the chronic hepatitis B patient - The effectiveness of peginterferon and the entecavir combination therapy
Kinki University School of Medicine0 个研究点目标入组 50 人开始时间: 2015年1月20日最近更新:
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 发起方
- 入组人数
- 50
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional,observational
入排标准
- 年龄范围
- 20years-old 至 80years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •*Under 20 years-old *Patients with the past of other IFN and nucleotide analog preparation dosage within the past one year *Patients with a history of the past of hypersensitivity for PEG-IFN-alpha2a or other IFN preparation *Patients with a history of the past of hypersensitivity for biological preparation such as vaccine *Patients with a history of the past of hypersensitivity for an ingredient of Entecavir *Pregnant or lactating patients *Other hepatitis patients like HCV/HDV/HIV *Other chronic liver diseases (autoimmune hepatitis, alcoholic hepatitis, and so on) *Failure of other organs and immunodeficiency patients *Patients with a history or in the presence of severe psychotic depression or other severe psychotic diseases patients *Inappropriate for this study patients
研究者
相似试验
未知
3 期
A study of peginterferon alfa-2a in combination with ribavirin in patients with chronic Hepatitis C.Chronic hepatitis CJPRN-jRCT2080220023Chugai Pharmaceutical Co., Ltd.
未知
2 期
A study of peginterferon alfa-2a in combination with ribavirin in chronic hepatitis C(CHC) patients with compensated liver cirrhosis(LC).CHC with compensated LCJPRN-jRCT2080220215Chugai Pharmaceutical Co., Ltd.
已完成
3 期
Effect of Pegylated Interferon alfa-2a plus Adefovir in the treatment of chronic hepatitis B with genotype DChronic hepatitis B.Chronic viral hepatitis B without delta-agentIRCT138711201155N4Guilan University of Medical Sciences74
已完成
3 期
The effect of Combination Peg interferon –alpha to Tenofovir versus each one of the treatment modalities alone on Patients with HBeAg-negative: A randomized clinical trialIRCT20181113041635N1vice presidency for siences and technology , Iran national silences foundation60
进行中（未招募）
1 期
Clinical study comparing treatment with nilotinib 600mg daily versus nilotinib 600 mg daily plus pegylated interferon-alpha 2a (PEG-IFN) in patients with Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase de novoChronic phase chronic myeloid leukaemia with Philadelphia chromosome positive or BCR-ABL positiveMedDRA version: 19.1Level: PTClassification code 10034877Term: Philadelphia chromosome positiveSystem Organ Class: 10022891 - InvestigationsMedDRA version: 19.1Level: LLTClassification code 10052065Term: Chronic phase chronic myeloid leukaemiaSystem Organ Class: 100000004864EUCTR2013-004974-82-FRHospices Civils de Lyon200